Labeling is one of the most common reasons pharmaceutical submissions to the Saudi Food and Drug Authority (SFDA) collect deficiency letters — and one of the most frequent triggers for post-market corrections. Saudi Arabia's pharmaceutical labeling requirements go beyond translating a European pack: Arabic-language rules, SmPC alignment, Braille, and the Kingdom's drug barcoding and serialization system all apply before a product can be marketed. This guide summarizes what the SFDA expects on pharmaceutical labels in Saudi Arabia and how labeling is managed through the product lifecycle.
Arabic labeling: the baseline requirement
Product information that reaches the patient must be available in Arabic. In practice this means the outer packaging and the patient information leaflet (PIL) are prepared in Arabic — typically alongside English — while the Summary of Product Characteristics (SmPC), directed at healthcare professionals, is submitted in English and must stay consistent with the approved dossier.
Consistency is the point the SFDA checks hardest: the label, leaflet, and SmPC must tell the same story. A claim, indication, or dosing statement on the pack that is not supported by the approved SmPC is a deficiency, and after approval it is a compliance finding.
What must appear on the pack
The core content the SFDA expects on pharmaceutical packaging includes:
- Product trade name, active ingredient(s) with strength, and pharmaceutical form.
- Route of administration and pack size/net content.
- Batch number, manufacturing and expiry dates, and storage conditions.
- Name and address of the manufacturer and the marketing authorization holder.
- SFDA registration details and required warnings — including legal status (prescription vs. OTC) and any class-specific warning statements.
- Braille labeling of the product name and strength, per the SFDA's Braille requirements for medicinal products for human use.
Barcoding and serialization
Saudi Arabia operates one of the region's most developed drug track-and-trace environments. Pharmaceutical packs must carry a GS1 Data Matrix barcode encoding the product identifier (GTIN), batch number, expiry date, and a unique serial number, in line with the SFDA's drug barcoding specifications, so each pack can be tracked through the Saudi supply chain.
For manufacturers, this is both an artwork question and an operations one: serialization data must be generated, printed, and reported correctly — and artwork must reserve compliant space and print quality for the Data Matrix. Packs that scan incorrectly at import are held regardless of how complete the registration file is.
Labeling in the registration dossier
Label artwork and the PIL are not an afterthought to the eCTD dossier — they are reviewed as part of it. Module 1 of the Saudi submission carries the proposed SmPC, patient leaflet, and mock-ups of the packaging, and deficiency letters on labeling are answered through the same SDR process as any other query.
The most efficient approach is to localize artwork early: build the Arabic label and leaflet against SFDA requirements during dossier preparation rather than retrofitting a CE or FDA pack after questions arrive.
After approval: label changes are variations
Every change to an approved label — new warnings, safety updates cascading from the SmPC, artwork revisions, pack-size additions — is submitted as a variation through the SDR system and must be approved before the revised pack is released to the Saudi market. Safety-driven updates carry expected implementation timelines, and marketing authorization holders are responsible for keeping distributed stock consistent with the currently approved artwork.
This makes labeling a lifecycle discipline: a tracking system for label versions across markets, with Saudi-specific requirements flagged, saves repeated remediation later.
How MRG supports pharmaceutical labeling compliance in Saudi Arabia
MRG's pharmaceutical team in Riyadh manages labeling end to end: Arabic label and PIL preparation and review, SmPC alignment, Braille and barcoding compliance checks, artwork mock-ups for the eCTD dossier, and post-approval label variations through the SDR system — under SFDA Consultation Office license CO-2023-FO-0022, with offices in Saudi Arabia, the UAE, and Egypt.
If you are preparing pharmaceutical labeling for the Saudi market, talk to our consultants about a gap review of your artwork before submission.
